Communicators

are winners!

More News

12.07.2021
Recce Pharmaceuticals Ltd.: Multiple Patients Dosed in Topical Phase I/II Clinical Trial
05.07.2021
Recce Pharmaceuticals Ltd.: Bonus Canadian Scientific Research & Experimental Development Rebate Received
07.06.2021
Recce Clinical Pipeline Update
27.05.2021
RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria
19.05.2021
RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
04.05.2021
Recce Pharmaceuticals Ltd: Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens
08.04.2021
Recce Pharmaceuticals: Positive Sinusitis Patient Update - Special Access Scheme
30.03.2021
Anti-Viral Patent Granted in Europe for RECCE® Anti-Infectives